|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM32011256X |
| 003 |
DE-627 |
| 005 |
20231225172902.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202007557
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1067.xml
|
| 035 |
|
|
|a (DE-627)NLM32011256X
|
| 035 |
|
|
|a (NLM)33448035
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jin, Qiutong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.10.2021
|
| 500 |
|
|
|a Date Revised 14.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Despite the critical breakthrough achieved by immune checkpoint blockade (ICB), the clinical benefits are usually restricted by inefficient infiltration of immune cells and immune-associated adverse effects. Noninvasive aerosol inhalation, as a definitive procedure for treatment of respiratory diseases, for ICB immunotherapy against lung metastasis, has not been realized to the best knowledge. Herein, an inhaled immunotherapeutic chitosan (CS)-antibody complex is developed for immunotherapy against lung cancer. In this system, CS is used as a carrier to assemble with anti-programmed cell death protein ligand 1 (aPD-L1) to enable efficient transmucosal delivery. Moreover, CS exhibits adjuvant effects to drive potent immune responses via activating the cyclic-di-GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway. Interestingly, repeated inhalation of CS/aPD-L1 complex can effectively activate the immune system by promoting the infiltration of different immune cells especially CD8+ T cells around tumor lesions, and finally prolongs the survival of mice to 60 days. Thus, the work presents a unique aerosol inhalation delivery system for ICB antibody, which is promising for immunotherapy against lung metastasis without the concern of systemic toxicity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a immune checkpoint blockade
|
| 650 |
|
4 |
|a inhalation
|
| 650 |
|
4 |
|a lung cancer
|
| 650 |
|
4 |
|a pulmonary drug delivery
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Immune Checkpoint Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Mucins
|2 NLM
|
| 650 |
|
7 |
|a Nanocapsules
|2 NLM
|
| 650 |
|
7 |
|a atezolizumab
|2 NLM
|
| 650 |
|
7 |
|a 52CMI0WC3Y
|2 NLM
|
| 650 |
|
7 |
|a Chitosan
|2 NLM
|
| 650 |
|
7 |
|a 9012-76-4
|2 NLM
|
| 650 |
|
7 |
|a N-Acetylneuraminic Acid
|2 NLM
|
| 650 |
|
7 |
|a GZP2782OP0
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Wenjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Jiafei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Junjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shen, Jingjing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Zhuang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Qian
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 7 vom: 15. Feb., Seite e2007557
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:7
|g day:15
|g month:02
|g pages:e2007557
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202007557
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 7
|b 15
|c 02
|h e2007557
|